Expert insights from Lisa Maffei Luther, Founder and Head of Regulatory Strategy at Advyzom, a Danforth Health company

For many biopharma companies, regulatory is often viewed as a critical – but contained – function: essential for approval, but less central once a product reaches the market.

In reality, regulatory plays an increasingly strategic role in how a product is communicated, adopted, and sustained over time.

From the earliest stages of commercialization planning through post-approval lifecycle management, regulatory sits at the intersection of science, compliance, and commercial impact. And when that connection isn’t fully integrated, companies can face real consequences — slower launches, inconsistent messaging, or increased regulatory risk.

The growing complexity of commercial regulatory

Today’s commercialization environment is more complex than ever:

• Promotional claims must be not only compelling, but fully aligned with evolving labeling and guidance
• Pre-launch scientific exchange requires careful navigation to avoid crossing into promotion
• Global considerations introduce additional layers of variability and risk
• Post-approval changes — from new indications to safety updates — require ongoing coordination across teams

At the same time, commercial teams are under pressure to move quickly, differentiate clearly, and engage stakeholders effectively.

Balancing these dynamics isn’t easy, and it’s no longer something that can be managed in silos.

Regulatory as a bridge — not a checkpoint

The most effective organizations are shifting their mindset:  Regulatory isn’t just a checkpoint at the end of the process — it’s a strategic partner throughout.

When regulatory is embedded early and works closely with commercial, medical, and market access teams, it can:

• Shape messaging strategies that are both impactful and compliant
• Translate complex labeling into clear, usable claims
• Anticipate and mitigate risk before it slows down execution
• Streamline review processes and reduce rework
• Support consistent, aligned communication across functions and markets

In this model, regulatory becomes a driver of efficiency and clarity, not just a gatekeeper.

The overlooked importance of post-approval strategy

Just as critical, and often underappreciated, is the role of regulatory after approval.

Maintaining a product’s value in-market requires continuous attention to:

• Labeling updates and evolving safety information
• Post-marketing requirements and commitments
• New data, indications, or formulations
• Shifts in the regulatory landscape

Without a proactive approach, these factors can create friction, delay opportunities, or even impact patient access.

With the right strategy in place, however, they become opportunities to extend value, strengthen positioning, and ensure continuity of care.

A more integrated path forward

As commercialization models evolve, the line between regulatory and commercial execution continues to blur.

Companies that succeed will be those that treat regulatory not as a constraint — but as an enabler of smarter, more effective commercialization.

That means building more integrated teams, aligning earlier in the process, and taking a lifecycle view of both compliance and value creation.

Because in today’s environment, getting regulatory right isn’t just about avoiding risk — it’s about unlocking the full potential of your product.